CLRB Cellectar Biosciences Inc.

1.97
+0.11  (+6%)
Previous Close 1.86
Open 2.05
Price To Book 1.32
Market Cap 10630191
Shares 5,396,036
Volume 1,131,804
Short Ratio
Av. Daily Volume 641,436

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

MM data February 25, 2019 noted 30% ORR. Further Phase 2 data from other cohorts due 2H 2019.
CLR 131
Various lymphoma
Phase 1 data from sixth cohort noted 50% partial response rate. Further data due 4Q 2019.
CLR 131
Multiple myeloma

Latest News

  1. Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
  2. Cellectar Biosciences Announces Closing of $10.0 Million Financing
  3. 5 Biotech Stocks to Watch in the Second Half of 2019
  4. Cellectar Biosciences Announces $10.0 Million Financing
  5. CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma
  6. Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
  7. Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update
  8. 5 Biotech Stocks With Near-Term Catalysts Ahead
  9. Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?
  10. 5 Oncology Companies That Are Set to Run
  11. FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients
  12. Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update
  13. Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131
  14. Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference
  15. Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference
  16. What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?
  17. Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
  18. Cellectar Biosciences to Present at the Biotech Showcase
  19. Cellectar Granted Japanese Patent for CLR 131
  20. Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma